Yeong In Kim

Yeong In Kim


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
JKJoong-Seok Kim
Joong-Seok Kim
SRSun-Young Ryu
Sun-Young Ryu
IYInjin Yun
Injin Yun
WKWoo-Jun Kim
Woo-Jun Kim
KLKwang-Soo Lee
Kwang-Soo Lee
YKYeong In Kim
Yeong In Kim
Kim JS, et al. J Clin Neurol. 2006 Dec;2(4):252-257. http://dx.doi.org/10.3988/jcn.2006.2.4.252

Hyeyun KimHyeyun Kim
Hyeyun Kim
JKJAYOUNG KIM
JAYOUNG KIM
HJHyo jin Ju
Hyo jin Ju
BJBong Jin Jang
Bong Jin Jang
TWTae Kyu Wang
Tae Kyu Wang
YKYeong In Kim
Yeong In Kim
Female hormone changes during menopause can affect the autonomic nervous system, circadian rhythm, and secretion of cortisol/melatonin, resulting in a vulnerability to insomnia. In this light, therapy has been gaining attention as a way to reduce stress hormones by stabilizing the autonomic nervous system. Thus, this study aims to objectively and scientifically analyze the impact of forest therapy in postmenopausal insomnia patients. The forest therapy program lasted 6 days, wherein 35 postmenopausal women performed activities such as trekking, leg massages, stretches, and bathing in warm and cold water. They also underwent serologic tests, participated in polysomnography (PSG), and answered sleep questionnaires before and after the program. Further, a statistical analysis compared the results. Serologic tests showed a significant reduction of cortisol from 10.2 ± 3.79 to 7.75 ± 2.81, while PSGs showed how sleep efficiency increased to 89.3 ± 4.3% (p < 0.01), and how waking after sleep onset reduced to 47.4 ± 22.3 min (p < 0.01). The total sleep time also increased to 428.5 min and sleep latency was 11.1 ± 11.0 min. Despite its limitations, forest therapy could be a good alternative to nonpharmacological treatment for mitigating insomnia in postmenopausal women.

1 April 2010 in Epilepsia
Verified
Journal Article
Closed access
PDF file
YSYoung‐Min Shon
Young‐Min Shon
YKYeong In Kim
Yeong In Kim
BKBang-Bon Koo
Bang-Bon Koo
JLJong‐Min Lee
Jong‐Min Lee
HKHye J. Kim
Hye J. Kim
DYDong W. Yang
Dong W. Yang

7 August 2008 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SLSeung-jae Lee
Seung-jae Lee
JKJoong-Seok Kim
Joong-Seok Kim
KLKwang-Soo Lee
Kwang-Soo Lee
JAJae-Young An
Jae-Young An
WKWoojun Kim
Woojun Kim
SJSo-Lyung Jung
So-Lyung Jung
Background: Several studies have suggested that the specific stroke subtype may influence the presence of leukoaraiosis in patients with ischemic stroke. We investigated the association between stroke subtype and leukoaraiosis in Korean patients with ischemic stroke by MRI. Methods: There were 594 patients included in this study that were classified as large artery disease, lacune and cardioembolic stroke. For large-artery disease, the analysis focused on the intracranial or extracranial location of the stenosis, and the multiplicity of the stenotic lesions. Leukoaraiosis grading was performed according to the Atherosclerosis Risk in Communities Study. Results: There was a significant association between leukoaraiosis and the stroke subtypes; the large-artery-disease group had a higher prevalence of leukoaraiosis than did the other groups (55.4% in the large-artery-disease group, 30.3% in the lacunar group and 14.3% in the cardioembolic group, P = 0.016 by chi-square test). On the multivariate linear regression analysis, age, the presence of hypertension, previous stroke and stroke subtype were independently associated with the presence of leukoaraiosis. In the sub analysis of the large-artery-disease group, the leukoaraiosis had a tendency to be more prevalent in the mixed and intracranial stenosis group than did the extracranial stenosis group (45.5% in the mixed group, 40.3% in the intracranial group and 26.9% in the extracranial group, P = 0.08 by chi-square test). Conclusion: The association of leukoaraiosis with large-artery disease in this study might be due to the relatively high prevalence of intracranial occlusive lesions in Korean stroke patients compared to other ethnic groups.

1 January 2009 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
HLHyun Joon Lee
Hyun Joon Lee
JKJi Seung Kang
Ji Seung Kang
YKYeong In Kim
Yeong In Kim
Lee HJ, et al. J Clin Neurol. 2009 Mar;5(1):33-38. http://dx.doi.org/10.3988/jcn.2009.5.1.33

1 October 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Hyeyun KimHyeyun Kim
Hyeyun Kim
HCHEEYONG CHOI
HEEYONG CHOI
Byong-Gon ParkByong-Gon Park
Byong-Gon Park
JHJu Hyojin
Ju Hyojin
YKYeong In Kim
Yeong In Kim
Background: Since the outbreak of the pandemic started, an increase in the number of sleep disorders, including insomnia and poor sleep quality, has been seen. The pattern will probably continue. Methods: This study focuses on the preparation and clinical testing of Poria cocos extract in treating suboptimal sleep quality. The optimal extraction method utilized a 75% ethanol concentration, and the clinical investigation involved subjects with defined poor sleep taking 800 mg of the extract nightly, assessed using the Sleep Questionnaire and polysomnography. The non-parametric Wilcoxon signed-rank test was used for statistical analysis due to the non-normal distribution of the collected data. Results: The study involved 21 insomnia sufferers with a mean age of 55 who were administered Poria cocos extracts. The findings of the study indicate a statistically significant rise in the overall duration of sleep (from 327.395 ± 43.2 min to 356.516 ± 63.21 min, p = 0.014). Additionally, there was a notable decrease in the level of arousal during sleep (from 76.316 ± 44.78 min to 47.989 ± 42.38 min, p = 0.009), and an improvement in the sleep severity index of the sleep questionnaire test. Conclusions: Poria cocos as a natural substance could improve quality of sleep, based on the findings. The study investigates Pachymic acid, a substance found in Poria cocos, as a potential indicator for the development of sleeping aids.